A recently conducted retrospective study by the Cancer Therapy Using Checkpoint Inhibitors in People Living with HIV-International (CATCH0IT) Consortium determined that immune checkpoint inhibitors were found to be safe and had "differential activity across tumour types." CATCH-IT enrolled 390 cancer patients with HIV into their cohort, "who received anti-PD-1 or anto-PD-L1 therapies and evaluated the safety and activity." This cohort was unique, as patients with HIV are at higher risk for developing cancer, due to dysfunctional immune systems. The 3 most common cancer identified in the cohort included non-small-cell lung cancer (28%), hepatocellular carcinoma (11%), and head and neck squamous cell carcinoma (10%). While the study authors acknowledged the relatively small sample size for this study, the results do support "the growing body of evidence [among] the use of ICIs [in] patients with HIV to enhance their inclusion in clinical studies."
To read more about this study, click here.
Source mentioned:
El Zarif T, Nassar AH, Adib E, et al. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. JCO; Published online 16 May 2023. DOI: 10.1200/JCO.22.02459
No comments:
Post a Comment